A clinical trial update dated September 18, 2026 reports the status of study NCT06317649. The trial, titled "Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)," is a Phase 2 study. Its current status is listed as recruiting. The trial is registered on ClinicalTrials.gov under identifier NCT06317649. No results have been posted as part of this update, and no efficacy or safety outcomes are described in the available record. This brief reflects only the recruitment status and trial design details as registered, without additional interpretation. Note that substance p is referenced in connection with this update but carries an unapproved research status, and no data regarding its use, dosing, or role in this specific trial were provided. Readers should treat this as a status notice rather than a report of clinical findings. For more background on substance p, including its general research context and regulatory standing, see the compound overview.
Trial Update: NCT06317649 Phase 2 AML Study Recruiting as of Sep 2026
See the full substance p overview
Source: https://clinicaltrials.gov/study/NCT06317649